NCT05949931View on ClinicalTrials.gov

Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2027

Conditions
Classic Hodgkin Lymphoma
Interventions
DRUG

Concurrent penpulimab and AVD

Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.

DRUG

Sequential penpulimab and AVD

Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER